Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Retained Earnings: 2010-2024

Historic Retained Earnings for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $71.7 million.

  • Anika Therapeutics' Retained Earnings fell 35.32% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.5 million, marking a year-over-year decrease of 35.32%. This contributed to the annual value of $71.7 million for FY2024, which is 44.03% down from last year.
  • Per Anika Therapeutics' latest filing, its Retained Earnings stood at $71.7 million for FY2024, which was down 44.03% from $128.1 million recorded in FY2023.
  • Anika Therapeutics' Retained Earnings' 5-year high stood at $225.6 million during FY2021, with a 5-year trough of $71.7 million in FY2024.
  • Over the past 3 years, Anika Therapeutics' median Retained Earnings value was $128.1 million (recorded in 2023), while the average stood at $136.8 million.
  • In the last 5 years, Anika Therapeutics' Retained Earnings increased by 1.87% in 2021 and then plummeted by 44.03% in 2024.
  • Over the past 5 years, Anika Therapeutics' Retained Earnings (Yearly) stood at $221.4 million in 2020, then climbed by 1.87% to $225.6 million in 2021, then decreased by 6.59% to $210.7 million in 2022, then slumped by 39.23% to $128.1 million in 2023, then slumped by 44.03% to $71.7 million in 2024.